In this video, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the current standard of care in mantle cell lymphoma (MCL), highlighting the various clinical presentations observed in this disease. Dr Dickinson first explains treatment approaches for younger, transplant-eligible patients, and then goes on to explain treatment approaches for transplant-ineligible patients, and the role of antibody maintenance therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
The current standard of care in mantle cell lymphoma
Теги
Speaker: Michael DickinsonInstitution: Peter MacCallum Cancer CentreEvent: SOHO 2022Format: InterviewSubject: LymphomaSubject: Non-Hodgkin lymphomaSubject: Mantle cell lymphomaField: TreatmentField: Immuno-OncologyField: TransplantationMedicines: RituximabMedicines: AntibodiesMedicines: Bendamustinetransplant-eligibletransplant-ineligibleallogeneic transplantmaintenance therapynext generation sequencingTP53